Infusystem Hld Stock Price, News & Analysis

InfuSystem Holdings (NYSE American: INFU) announced its participation in the upcoming Sidoti Small Cap Virtual Investor Conference on December 4, 2024. The company's leadership team, including CEO Richard DiIorio, CFO Barry Steele, and President/COO Carrie Lachance, will present at 10:00 a.m. ET.

The presentation will be available via webcast on the company's investor relations website, with a replay option available post-event. Management will also host one-on-one meetings throughout the day. InfuSystem operates under two platforms: Patient Services (providing clinic-to-home healthcare solutions) and Device Solutions (supporting direct payer clients with rentals, sales, and biomedical services).

InfuSystem Holdings (NYSE American: INFU) has appointed Ronald Hundzinski as an independent director to its Board of Directors, effective November 12, 2024. Hundzinski, who will serve until the next Annual Shareholders meeting in May 2025, brings significant financial expertise and operational experience. He currently serves as Chairman of Gentherm's Board of Directors and previously held CFO positions at TI Fluid Systems, Tenneco Inc., and BorgWarner. The appointment strengthens InfuSystem's board oversight with his extensive accounting, finance, and operational expertise in healthcare services.

InfuSystem Holdings reported strong Q3 2024 financial results with record net revenues of $35.3 million, up 11% year-over-year. Net income increased 162% to $1.8 million ($0.08 per diluted share). Patient Services revenue grew 8% to $20.8 million, while Device Solutions revenue rose 15% to $14.5 million. The company's gross margin improved to 53.9%, up 5.0%. Adjusted EBITDA reached $7.9 million, increasing 27% with margin expansion to 22.3%. Operating cash flow surged 91% to $12.5 million. The company entered new strategic partnerships with Smith+Nephew for wound therapy and became exclusive distributor of Chemo Mouthpiece® through SI Healthcare Technologies joint venture.

InfuSystem Holdings (NYSE American: INFU) announced it will release its third quarter 2024 financial results on November 7, 2024, before market open. The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results. InfuSystem operates through two platforms: Patient Services, providing clinic-to-home healthcare solutions for complex medical equipment, and Device Solutions, supporting direct payer clients with rentals, sales, and biomedical services.

InfuSystem Holdings, Inc. (NYSE American: INFU) announced its participation in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. Key executives, including CEO Richard DiIorio, President and COO Carrie Lachance, and CFO Barry Steele, will be present. A webcasted fireside chat with DiIorio is scheduled for 3:30pm ET.

The webcast will be accessible via the conference website and InfuSystem's investor relations page. Management will be available for one-on-one and group meetings with investors. InfuSystem is a leading national health care service provider operating under two platforms: Patient Services and Device Solutions. The company facilitates outpatient care for durable medical equipment manufacturers and health care providers, with a focus on oncology, pain management, and wound therapy.

InfuSystem Holdings (NYSE American: INFU) and Sanara MedTech have announced an exclusive U.S. distribution agreement with ChemoMouthpiece, Their joint venture, SI Healthcare Technologies, will distribute ChemoMouthpiece's FDA-cleared oral cryotherapy device to approximately 3,000 cancer centers through InfuSystem's Oncology sales team.

The device aims to reduce oral mucositis in patients undergoing chemotherapy. Sanara invested $5 million for a 6.6% ownership in ChemoMouthpiece. The U.S. market for oral mucositis treatment is estimated at over $600 million annually, affecting 500,000 to 1 million patients. The American Medical Association has issued a CPT code (effective July 2024) for potential reimbursement of oral cavity cryotherapy devices used with chemotherapy.

InfuSystem Holdings (NYSE American: INFU) announced its participation in Lake Street Capital Markets' 8th Annual Best Ideas Growth (BIG8) Conference on September 12, 2024, at The Yale Club in New York City. CEO Richard DiIorio and CFO Barry Steele will be available for one-on-one and group meetings with investors throughout the day.

InfuSystem is a leading national health care service provider facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company operates under two platforms: Patient Services (Oncology, Pain Management, and Wound Therapy) and Device Solutions (direct payer rentals, pump and consumable sales, and biomedical services).

Headquartered in Rochester Hills, Michigan, InfuSystem delivers local, field-based customer support and operates Centers of Excellence across the United States and Canada.

InfuSystem Holdings (NYSE American:INFU) reported strong Q2 2024 financial results, with record net revenues of $33.7 million, up 6% year-over-year. Key highlights include:

- Patient Services revenue increased 5% to $20.2 million
- Device Solutions revenue grew 8% to $13.5 million
- Net income rose 64.8% to $0.7 million, or $0.03 per diluted share
- Adjusted EBITDA increased 5% to $6.1 million
- Net operating cash flow up 17% to $2.7 million

The company reaffirmed its full-year 2024 guidance, projecting high-single-digit revenue growth and Adjusted EBITDA margin in the high-teens. InfuSystem's CEO highlighted the company's strategic partnerships and diversification efforts, including a new distribution agreement with Smith+Nephew.

InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a three-year distribution agreement with Smith+Nephew for its negative pressure wound therapy (NPWT) system. InfuSystem will offer Smith+Nephew's advanced RENASYS◊ EDGE NPWT system, a lightweight and compact option for home-based care of chronic wounds.

The partnership leverages InfuSystem's Patient Services platform and network of over 800 in-network health insurance providers, covering 96% of the U.S. population. This collaboration aims to increase patient access to the RENASYS EDGE technology and create new revenue opportunities for both companies.

InfuSystem's CEO, Richard DiIorio, emphasized the company's ability to provide customized solutions and high-value services around partners' products, making them an attractive secondary distribution partner for Smith+Nephew's NPWT system.